DIRS.INFO The most relevant business & tech news

☆ WADA outlaws tramadol use from 2024, maintains cannabis ban
▼ + stars: | 2022-09-23 | by ( ) www.reuters.com time to read: +2 min

A pharmacist holds a bottle of traMADOL Hydrochloride made by Sun Pharma at a pharmacy in Provo, Utah, U.S., May 9, 2019. REUTERS/George Frey/FilesSYDNEY, Sept 23 (Reuters) - The World Anti-Doping Agency will add the painkiller tramadol to the list of banned substances for athletes in competition from 2024 and has maintained its ban on cannabis after a review. Register now for FREE unlimited access to Reuters.com Register"Research studies funded by WADA have also confirmed the potential for tramadol to enhance physical performance." WADA said the delay in introducing the ban until 2024 was to allow the communication of the implications of it to athletes, their entourages and medical staff. After requests from some "stakeholders", however, WADA agreed to review the cannabis ban but decided on Friday to maintain it because the use of the drug "violated the spirit of sport".

☆ Haleon rejects Zantac indemnification requests from GSK, Pfizer
▼ + stars: | 2022-09-20 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Brendan McDermidLONDON, Sept 20 (Reuters) - Haleon (HLN.L) on Tuesday said it had notified GSK (GSK.L) and Pfizer (PFE.N) that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac. More than 2,000 legal cases related to Zantac have been filed in the United States over allegations that the compound contains a probable carcinogen. Zantac, originally marketed by a forerunner of GSK, has been sold by several companies at different times, including Pfizer, Boehringer Ingelheim and Sanofi (SASY.PA) as well as a plethora of generic drugmakers. Haleon - alongside GSK, Sanofi and Pfizer - saw billions wiped off their market value last month as uncertainty around the outcome of the impending litigation triggered investor concern, although some of those losses have been since pared back. However, in August, Haleon clarified that it never marketed Zantac in any form in the U.S., either as Haleon or as GSK consumer healthcare.

Johnson & Johnson has said it would provide a fair amount of money to the subsidiary to pay claims. Johnson & Johnson, valued at more than $450 billion, had about $31 billion in cash and marketable securities on hand at the end of the third quarter, securities filings show. One would absorb all the talc liability; the other would carry on the business free from the threat of billion-dollar judgments. Levesque replied that the “technical aspect” of the subsidiary bankruptcy wasn’t likely to cause concern about J&J’s creditworthiness. Is that what you're saying?” asked Jeffrey Jonas, a Brown Rudnick lawyer representing a creditors committee comprising talc plaintiffs.

Organizations: & $, & &

☆ Opioid Crisis Fast Facts
▼ + stars: | 2017-09-18 | by ( Cnn Editorial Research | ) edition.cnn.com time to read: +15 min

March 29, 2017 - Trump signs an executive order calling for the establishment of the President’s Commission on Combating Drug Addiction and the Opioid Crisis. April 9, 2018 - The US surgeon general issues an advisory recommending that Americans carry the opioid overdose-reversing drug, naloxone. The settlement will be used to fund addiction research and help cities and counties with the opioid crisis. Cleveland County District Judge Thad Balkman orders Johnson & Johnson to pay $572 million for its role in the state’s opioid crisis. November 15, 2022 - Walmart agrees to the framework of a $3.1 billion settlement, which resolves allegations from multiple states’ attorneys general that the company failed to regulate opioid prescriptions contributing to the nationwide opioid crisis.

Search resuls for: "painkiller"

4 mentions found